Loading...

APC anti-human CD107a (LAMP-1) Antibody

Pricing & Availability
Clone
H4A3 (See other available formats)
Regulatory Status
RUO
Workshop
P PR-63; BP 473; P P008
Other Names
Lysosome-Associated Membrane Protein 1, LGP-120, LAMP-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
H4A3_APC_110308.jpg
Thrombin-activated human peripheral blood platelets were stained with CD107a (clone H4A3) APC (pink histogram) or mouse IgG1, κ APC (blue histogram).
  • H4A3_APC_110308.jpg
    Thrombin-activated human peripheral blood platelets were stained with CD107a (clone H4A3) APC (pink histogram) or mouse IgG1, κ APC (blue histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
328619 25 tests 120€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
328620 100 tests 252€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD107a, also known as Lysosome-Associated Membrane Protein 1 (LAMP-1) or LGP-120, is a 110-140 kD type I membrane glycoprotein. Mature CD107a is heavily glycosylated from a 40 kD core protein. This molecule is located on the luminal side of lysosomes. Upon activation, CD107a is transferred to the cell membrane surface of activated platelets, activated lymphocytes, macrophages, epithelial cells, endothelial cells, and some tumor cells. CD107a has been suggested to play a role in the protection of lysosomal membrane from lysosomal hydrolases which is involved in cell adhesion and regulation of tumor metastasis, and mediates autoimmune disease progression. CD107a is a ligand for galaptin and E-selectin. Surface expression of LAMP-1 has been shown to correlate with CD8+ T cell and NK cell cytotoxicity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Cynomolgus, Pigtailed Macaque, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human adult adherent peripheral blood cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: Western blotting8, immunohistochemical staining2, immunofluorescence5,7, and immunoprecipitation5.

This antibody is specific to human LAMP-1. Positive control: Hela cells; LAMP-1 molecular weight appears to be at ~110 kDa on the gel due to high glycosylation.

Application References
  1. Misse D, et al. 1999. Blood 93:2454.
  2. Furuta K, et al. 2001. Am. J. Pathol. 159:449. (IHC)
  3. Watanabe A, et al. 2011. J. Biol. Chem. 286:10702. PubMed
  4. Baron Gaillard CL, et al. 2011. Mol. Cell. Biol. 22:5459. PubMed
  5. Hauck CR and Meyer TF. 1997. FEBS Lett. 405:86. (IF, IP)
  6. De Keersmaecker B, et al. 2012. J. Virol. 86:9351. PubMed
  7. Knodler LA, et al. 2010. P. Natl. Acad. Sci. USA. 107:17733. (IF)
  8. Oh J, et al. 2000. Hum. Mol. Genet. 9:375. (WB)
  9. Salio M, et al. 2013 PNAS. 110:4753. PubMed
Product Citations
  1. Fowler DW, et al. 2017. Cancer Immunol Immunother. 66:1205. PubMed
  2. Buijsers B, et al. 2022. Front Immunol. 12:759570. PubMed
  3. Li Y, et al. 2022. J Oncol. 2022:4544773. PubMed
  4. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  5. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  6. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  7. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  8. Ali A, et al. 2020. J Infect Dis. 222:853. PubMed
  9. Xun X, et al. 2021. Am J Transl Res. 13:4360. PubMed
  10. Ma KY, et al. 2021. Nat Immunol. 22:1590. PubMed
  11. Yan LM, et al. 2020. MBio. 11:. PubMed
  12. Diab M, et al. 2020. Viruses. :12. PubMed
  13. Izumi K, et al. 2021. Immunohorizons. 5:687. PubMed
  14. Song C, et al. 2022. Stem Cell Res Ther. 13:48. PubMed
  15. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  16. Zhou Y, et al. 2017. Front Cell Infect Microbiol. 7:457. PubMed
  17. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  18. Gujar S, et al. 2010. Mol Cancer Ther. 2.405555556. PubMed
  19. Sahillioglu AC, et al. 2021. Cancer Immunol Res. 9:999. PubMed
  20. Wu D, et al. 2020. Biomark Res. 8:3. PubMed
  21. Guo M, et al. 2021. Front Oncol. 11:632540. PubMed
  22. Vinton C, et al. 2017. J Immunol. 10.4049/jimmunol.1700136. PubMed
  23. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  24. Harper JL, et al. 2020. Nat Med. 519:26. PubMed
  25. Ding R, et al. 2021. Theranostics. 4957:11. PubMed
  26. Peluso MJ, et al. 2021. Cell Rep. 36:109518. PubMed
  27. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  28. Guo S, et al. 2021. Stem Cells Int. 2021:9989790. PubMed
  29. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  30. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  31. Han F, et al. 2022. Cent Eur J Immunol. 46:427. PubMed
  32. Elias S, et al. 2020. Haematologica. . PubMed
  33. Georg P, et al. 2022. Cell. 185:493. PubMed
  34. López-Sanz C, et al. 2022. STAR Protoc. 3:101755. PubMed
  35. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  36. Montel‐Hagen A et al. 2019. Cell stem cell. 24(3):376-389 . PubMed
  37. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  38. Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed
  39. Iraqi M, et al. 2020. Front Cell Infect Microbiol. 10:48. PubMed
  40. Rambaldi B, et al. 2022. Haematologica. 107:2617. PubMed
  41. Ochi T, et al. 2015. Cancer Immunol Res. 3: 1070-1081. PubMed
  42. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  43. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  44. Sasawatari S, et al. 2020. J Immunol. 1373:204. PubMed
  45. Gruijs M, et al. 2021. Int J Mol Sci. 22:. PubMed
  46. Dao TN, et al. 2020. Cancers (Basel). 12:00. PubMed
RRID
AB_1279055 (BioLegend Cat. No. 328619)
AB_1279055 (BioLegend Cat. No. 328620)

Antigen Details

Structure
LAMP-1 is a 417 amino acid protein with a molecular mass of 45 kD.
Distribution

Macrophages, epithelial cells, endothelial cells, some tumor cells; located on the luminal side of lysosomes or on the surface of cell membranes

Function
Protect lysosomal membrane from lysosomal hydrolases, adhesion
Ligand/Receptor
Galaptin
Cell Type
Endothelial cells, Epithelial cells, Macrophages
Biology Area
Cell Biology, Immunology, Neurodegeneration, Neuroscience, Protein Trafficking and Clearance
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Sarafian V, et al. 2006. Arch. Dermatol. Res. 298:7381.
2. Schlossman SF, et al. 1995. Leukocyte Typing V:White Cell Differentiation Antigens. New York:Oxford University Press.
3. Sawada R, et al. 1993. J. Biol. Chem. 268:12675.
4. Chen JW, et al. 1988. J. Biol. Chem. 263:8754.
5. Chen JW, et al. 1986. Biochem. Soc. Symp. 51:97112.

Gene ID
3916 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD107a
Specificity Alt (DOES NOT SHOW ON TDS):
CD107a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD107a on UniProt.org
Go To Top Version: 2    Revision Date: 10.22.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account